Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

MICS and MIGS with XEN gel stent

Search Title by author or title

Session Details

Session Title: Glaucoma I

Session Date/Time: Sunday 11/09/2016 | 14:30-16:00

Paper Time: 15:12

Venue: Auditorium C6

First Author: : A.Amisano ITALY

Co Author(s): :    S. Morselli   A. Toso                 

Abstract Details


We sought to reduce the number of medications and to control the IOP in POAG patients not controlled by medications or with poor drug compliance.


Department of Ophthalmology at San Bassiano Hospital (Bassano del Grappa, Italy)


We performed the MICS and MIGS combined surgery with the implantation of XEN Gel Stent in 27 eligible eyes. After surgery we provided a 1 year-follow up, including anterior OCT (with the DRI OCT Triton plus - Topcon Medical Japan Co., Ltd.).


IOP was reduced from 25.8 mmHg ± 5.26 mmHg (mean ± standard deviation) at baseline before surgery to 13.8 ± 1.09 mmHg one year after surgery. Furthermore, the mean number of glaucoma medications was reduced from 2.6 at baseline before surgery to 0 at 1 year. The reduction of IOP has persisted and we have experienced no major complications. There was just one patient, who had not interrupted antiplatelet therapy although preoperative discontinuation was required, in whom we did not succeed in implanting the device because of a diffuse sub-conjunctival haemorrhage soon after mitomycin-C injection.


In patients with mild–moderate glaucoma with an IOP that has been unable to be controlled by medications or who have poor medication compliance, MICS and MIGS appear to be a viable option.

Financial Disclosure:


Back to previous